[ad_1]

Duvelisib extended progression – free survival to 13.3 months versus 9.9 months for ofatumumab

Related Links:

SummaryChronic lymphocytic leukaemia (CLL) is characterized by expression of CD5 on clonal B cells, and is partly driven by activated B ‐cell receptor (BCR) signalling. While CD5 is known to be a negative regulator of BCR signalling, it is unknown if variability in CD5 expression exists among patients and whether CLL cell CD5 expression affects CLL clinical outcomes. We assessed the extent to which CD5 expression is correlated wit h clinical outcomes, and whether this information adds to currently used prognostic markers. We evaluated CD5 expression from 1275 blood samples, established prognostic markers and time to even…

Source: British Journal of HaematologyCategory: Hematology Authors: Tags: Research Paper Source Type: research

British Journal of Haematology, EarlyView.

Source: British Journal of HaematologyCategory: Hematology Authors: Tags: Correspondence Source Type: research

Earn CME: https://naccme.com/program/…In this Key Insights activity, Drs. Morton Coleman and Richard R. Furman discuss CLL-related highlights from Lymphoma &Myeloma 2018: An International Con…


Author: imedex
Added: 11/07/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Drug: BGB-3111;   Drug: Ibrutinib Sponsor:   BeiGene Recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   Relapsed or Refractory Chronic Lymphocytic Leukemia Interventions:   Drug: Ibrutinib;   Drug: Daratumumab Sponsors:   French Innovative Leukemia Organisation;   Janssen, LP Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Drug: BGB-3111;   Drug: Ibrutinib Sponsor:   BeiGene Recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   Relapsed or Refractory Chronic Lymphocytic Leukemia Interventions:   Drug: Ibrutinib;   Drug: Daratumumab Sponsors:   French Innovative Leukemia Organisation;   Janssen, LP Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. BarrAbstractBackgroundAs oral targeted agents, such as ibrutinib, become more widely used, understanding the impact of suboptimal dosing on overall survival (OS) and progression-free survival (PFS) outside of clinical trials is imperative.Patients and MethodsData on ibrutinib discontinuation, dose reductions, and treatment interruptions were collected on …

Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and progressive accumulation of mature B lymphocytes in the peripheral blood, lymphoid tissues, and bone marrow. CLL is characterized by profound immune defects leading to severe infectious complications. T cells are numerically, phenotypically, and functionally highly abnormal in CLL, with only limited ability to exert antitumor immune responses. Exhaustion of T cells has also been suggested to play an important role in antitumor responses. CLL-mediated T cell exhaustion is achieved by the aberrant expression of several inhibitory molecules on CLL…

Source: Journal of Clinical InvestigationCategory: Biomedical Science Authors: Source Type: research

AbstractBruton ’s tyrosine kinase (BTK) is crucial in B-cell development and survival. The role of BTK as a downstream kinase in the B-cell receptor (BCR) signaling pathway is well described. As a key player in the pathogenesis of B-cell malignancies, targeting of dysregulated BCR signaling has been explored by development of inhibitors of downstream mediators. Discovery of the biological function of BTK and the development of covalent inhibitors for clinical use, ibrutinib as the lead agent and acalabrutinib as the second clinically approved BTK inhibitor, have revolutionized the treatment options for B-c ell malign…

Source: DrugsCategory: Drugs & Pharmacology Source Type: research

[ad_2]

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here